MORTALITA’ DA COVID-19 vs INFLUENZA: 206 vs 1.8 per 100 000 da BMJ ( GRAN BRETAGNA ED USA).

Covid and flu: what do the numbers tell us about morbidity and deaths? Much confusion has been seen in the UK media about the effects on mortality of flu and covid-19. Gareth Iacobucci Are there more deaths from flu than from covid? Data from the Office for National Statistics show that in England and Wales…

LO SCENARIO ECONOMICO DELLA CIRROSI COMPENSATA E SCOMPENSATA: UN ALLARMANTE QUADRO DI REAL-WORLD EVIDENCE DA UNO STUDIO ITALIANO SULLA CAMPANIA

Burden of compensated and decompensated cirrhosis: real world data from an Italian population-based cohort study S Cammarota et al. Abstract Objective: To quantify the annual healthcare resource utilization, costs and mortality rate for a large cohort of Italian patients with compensated (CC) and decompensated cirrhosis (DC). Patients and methods: A population-based cohort study was conducted through the…

LINEE GUIDA DELLA “AMERICAN SOCIETY OF COLON AND RECTAL SURGEONS” PER LA MALATTIA DIVERTICOLARE

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis Jason Hall et al. The American Society of Colon and Rectal Surgeons (ASCRS) is dedicated to ensuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus.…

NUOVI “TARGET” PER LA COLESTASI E LA STEATOSI. UNA GRANDE REVISIONE DA “GUT” (FREE!)

Novel therapeutic targets for cholestatic and fatty liver disease Michael Trauner , Claudia Daniela Fuchs Abstract Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas. Nuclear receptors (NRs) are ligand-activated transcriptional regulators of key metabolic processes including hepatic…

MALATTIA DIVERTICOLARE : UN EDITORIALE EVIDENCE-BASED 2020 DA DIS COLON RECTUM

Evidence-Based Management of Diverticular Disease: What’s New and What’s Missing? David R. Flum, • Thomas E. Read   IT seems the more we learn about diverticulitis, the less we know. In this month’s Diseases of the Colon & Rectum, “The American Society of Colon and Rectal Surgeons (ASCRS) Clinical Practice Guidelines for the Treatment of…

MICROBIOMA E TERAPIE INDIVIDUALIZZATE: IL FUTURO E’ GIA’ QUI ! UNA REVISIONE DA “NATURE GASTRO&HEPATOL”

The promise of the gut microbiome as part of individualized treatment strategies Daniel A. Schupack, et al. Abstract Variability in disease presentation, progression and treatment response has been a central challenge in medicine. Although variability in host factors and genetics are important, it has become evident that the gut microbiome, with its vast genetic and…